SCHEMBL2687042

SCHEMBL2687042

Cc1nc2cc(-c3nc4ccccc4o3)ccc2n1CC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.46
▸ KDM4E B2RXH2 7/20 0.46
▸ ALDH1A1 P00352 6/20 0.46
▸ HPGD P15428 5/20 0.46
▸ SMN1; SMN2 Q16637 5/20 0.46
▸ RAB9A P51151 5/20 0.46
▸ HCRTR1 O43613 2/20 0.46
▸ NFKB1 P19838 2/20 0.46
▸ STAT1 P42224 2/20 0.46
▸ NFKB2 Q00653 2/20 0.46
▸ RELA Q04206 2/20 0.46
▸ HSD17B10 Q99714 4/20 0.46
▸ USP2 O75604 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687383 0.87 KDM4E (0.55) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2686523 0.85 KDM4E (0.48) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL16015597 0.84 NPC1 (0.45) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2687478 0.84 TNF (0.58) KDM4EALDH1A1RAB9AMAPTMEN1
SCHEMBL10219624 0.84 NPC1 (0.49) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2688624 0.84 KMT2A (0.53) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2688713 0.83 NPC1 (0.44) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2687005 0.83 KDM4E (0.47) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
Hydrochloric Acid SCHEMBL2686319 0.83 NPC1 (0.48) NPC1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2686759 0.82 NPC1 (0.49) NPC1KDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 — — EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 NPC1 525/4885KDM4E 4538/4885ALDH1A1 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback